ifinatamab – Talk Bio

FDA Lifts Partial Hold on Merck and Daiichi Sankyo’s B7-H3 ADC Trial for Lung Cancer[6]

2 weeks ago talkbio0Tagged CD276 gene, Daiichi, Deruxtecan, I-DXd, IDeate-Lung02, ifinatamab, Lifting, Merck, Sankyo, Small cell carcinoma of lung, therapeutic autologous dendritic cells, United States Food and Drug Administration

FDA; partial hold lifted; Merck; Daiichi Sankyo; ifinatamab deruxtecan; I-DXd; B7-H3 ADC; small cell lung cancer; IDeate-Lung02

FDA places partial clinical hold on Merck and Daiichi Sankyo’s I-DXd lung cancer trial after interstitial lung disease deaths

1 month ago talkbio0Tagged Antibody-Drug Conjugates, Clinical Trials, Daiichi, Deruxtecan, grade 5 ILD, I-DXd, IDeate-Lung02, ifinatamab, Lung Diseases, Interstitial, Merck, Partial, Sankyo, Small cell carcinoma of lung, United States Food and Drug Administration

FDA partial clinical hold; ifinatamab deruxtecan; I-DXd; IDeate-Lung02; Merck; Daiichi Sankyo; small cell lung cancer; interstitial lung disease; grade 5 ILD; antibody-drug conjugate; clinical trial deaths

Daiichi and Merck’s Lung Cancer ADC Achieves 48% Response Rate in Pivotal Trial

5 months ago talkbio0Tagged Accelerated, Antibody-Drug Conjugates, Approved, Breakthrough Therapy, CD276 gene, Co., Daiichi, Deruxtecan, Frequency of Responses, IDeate-Lung01, Identifier, ifinatamab, Overall Survival, Progression-Free Survival, Sankyo, Small cell carcinoma of lung, therapeutic autologous dendritic cells, United States Food and Drug Administration

Daiichi Sankyo; Merck & Co.; ifinatamab deruxtecan; I-DXd; B7-H3; antibody-drug conjugate; ADC; small cell lung cancer; SCLC; IDeate-Lung01; objective response rate; accelerated approval; progression-free survival; overall survival; FDA Breakthrough Therapy Designation